Age, anthracycline and mortality in 28,000 classic Hodgkin lymphoma patients: cohort study of a complete population

Classic Hodgkin lymphoma (CHL) has an excellent prognosis in younger patients but outcomes are poorer in those aged ≥60 years at diagnosis. We used routinely collected English data to assess baseline characteristics, survival and treatment approaches in 28 175 patients with CHL registered between 1997 and 2020 with a particular focus on 1 958 patients aged 60 to 79 years at diagnosis with known first-line chemotherapy regimens. Mortality rates (all causes, lymphoma-specific and other causes) were calculated first without and then with adjustment for available characteristics to identify factors associated with survival. Survival outcomes for younger patients were better than older (p.